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Abstract
Background: Hereditary nonpolyposis colorectal cancer (HNPCC), or Lynch syndrome, accounts for 3 % of newly
diagnosed cases of colorectal cancer. While a partial or subtotal colectomy is indicated for early stage disease, there
is a paucity of data addressing locally advanced disease involving the foregut.
Case presentation: We report two patients with hereditary nonpolyposis colorectal cancer presenting with locally
advanced colon cancer surgically managed by pancreaticoduodenectomy with en bloc partial colectomy and a
review of the literature.
Conclusions: Locally advanced colorectal cancer in HNPCC is a rare clinical entity that requires special surgical
consideration. Multidisciplinary treatment, including multi-visceral resection, offers the best long-term outcome.
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nonpolyposis colorectal cancer, Lynch syndrome, Pancreaticoduodenectomy, Whipple procedure
Background
Colorectal cancer (CRC) associated with hereditary
nonpolyposis colorectal cancer (HNPCC) accounts for
3 % of newly diagnosed cases. It is genetically driven by
an autosomal dominant mutation of DNA mismatch re-
pair (MMR) genes and has a phenotypic penetrance of
70–80 % [1]. While a partial or subtotal colectomy may
be indicated in early stage cancers, there is a paucity of
data addressing locally advanced disease involving the
foregut. We report two cases and review the literature
in the management of this rare clinical entity.
Case presentation
Case no. 1
A healthy 56-year-old male presented with a 6-month
history of early satiety, fatigue, and 80-pound weight
loss. His mother and brother died from CRC at ages 36
and 44, respectively, and sister died from endometrial
cancer. Physical exam revealed a firm, right upper quad-
rant mass.
Laboratory data included a hematocrit level of 32.7 %
(normal 40–52 %) and carcinoembryonic antigen (CEA)
level of 50.28 ng/dL (normal <3.0 ng/dL). Computed tom-
ography (CT) of the chest, abdomen, and pelvis revealed a
13.0 × 10.0 cm localized right upper quadrant mass arising
from the ascending colon proximal to the hepatic flexure,
indistinguishable from the duodenum, and invading the
right lateral abdominal wall. Colonoscopy revealed a large,
nearly obstructing mass proximal to the hepatic flexure,
and esophagogastroduodenoscopy showed a mass in the
duodenum. Biopsies from both endoscopies revealed mu-
cinous lesions suspicious but not diagnostic of adenocar-
cinoma. Neither the positron emission tomography (PET)
nor the pre-operative laparoscopy showed evidence of
metastatic disease. Neoadjuvant chemotherapy was not
pursued due to lack of histologic confirmation of malig-
nancy. Prior to surgery, he was admitted with a lower ex-
tremity deep vein thrombosis (DVT), for which he
received an inferior vena cava (IVC) filter and therapeutic
anticoagulation with enoxaparin.
The patient underwent a right hemicolectomy with en
bloc classic pancreaticoduodenectomy and resection and
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reconstruction of the anterior abdominal wall. Reconstruc-
tion involved an end-to-side pancreaticojejunostomy, hepa-
ticojejunostomy, gastrojejunostomy, and ileocolostomy. He
had an unremarkable post-operative course. Histopathology
of the surgical specimen revealed moderately differentiated
mucinous adenocarcinoma arising from the hepatic flexure
of the colon with focal invasion into a segment of the adja-
cent small bowel, peripancreatic soft tissues, and duode-
num. Seventy-six lymph nodes and all surgical resection
margins were negative for tumor. Immunohistochemistry
of the surgical specimen showed absence of DNA mis-
match repair enzymes hMLH1 and hPMS2 with retention
of normal hMSH2 and hMSH6. Polymerase chain reaction
(PCR) was consistent with high microsatellite instability
(MSI-H) in the tumor. Genetic testing of peripheral blood
leukocytes was consistent with mutated hMLH1. He under-
went adjuvant chemotherapy with 12 cycles of oxaliplatin,
fluorouracil, and folinic acid (FOLFOX) chemotherapy. He
remains free of disease 4.5 years after surgery.
Case no. 2
A healthy 36-year-old male presented with fatigue, vague
abdominal pain, diarrhea, and unintentional 40-pound
weight loss. He was profoundly anemic with hemoglobin
4.2 g/dL (normal 13.0–18.0 g/dL), and CT demonstrated
a 14-cm heterogeneous mass in the right hemi-abdomen
(Fig. 1). Colonoscopy revealed a partially obstructing tumor
near the hepatic flexure (Fig. 2a), biopsies were consistent
with adenocarcinoma, and immunohistochemistry revealed
the absence of DNA mismatch repair enzymes hMSH2 and
hMSH6 with retention of normal hMLH1 and hPMS2.
Upper endoscopy revealed a 7-cm partially obstructing ul-
cerated mass in the second part of the duodenum (Fig. 2b);
biopsies revealed a well-differentiated adenocarcinoma with
immunostains suggesting a colonic primary (CK20/CDX2-
positive, CK7-negative). Tumor markers were remarkable
for an elevated CEA level of 46.3 ng/dL (normal <3.0 ng/
dL). Neoadjuvant chemotherapy with oxaliplatin, fluo-
rouracil, iniontecan, and leucovorin (FOLFIRINOX)
was administered but the patient only received 3 cy-
cles. This treatment was complicated by gastrointes-
tinal bleeding and bilateral pulmonary emboli after
bilateral lower extremity DVTs. Anticoagulation was
initially contraindicated, so an IVC filter was placed.
The third cycle of chemotherapy was complicated by a
perirectal abscess requiring drainage. Poor nutritional
parameters prompted aggressive enteral feeds via a nasoje-
junal feeding tube (pre-albumin 16 mg/dL (normal 18.5–
35.8 mg/dL), albumin 2.8 g/dL (normal 3.4-5.4 g/dL)). His
CEA level decreased to 22.7 ng/dL (normal <3.0 ng/dL).
The patient underwent a pylorus sparing pancreati-
coduodenectomy with en bloc right hemicolectomy.
Reconstruction involved an end-to-side pancreaticoje-
junostomy, end-to-side hepaticojejunostomy, end-to-
side duodenojejunostomy, and anatomical side-to-side and
functional end-to-end ileocolostomy. Examination of the
specimen revealed mucinous adenocarcinoma arising from
the right colon with direct extension to the duodenal mu-
cosa (Fig. 2c, d), and histopathology showed absence of
DNA mismatch repair and high microsatellite instability
(MSI-H). Twenty-two lymph nodes and all surgical resec-
tion margins were negative for tumor. There was no defini-
tive tumor response to treatment. Post-operative course
was remarkable only for a grade A pancreatic fistula that
was successfully managed by percutaneous drainage and
subcutaneous octreotide. He was discharged on post-
operative day 8 on rivaroxaban in light of his continued
need for anticoagulation. The patient completed 4 months
of adjuvant chemotherapy and remains well without evi-
dence of recurrence 2 years after surgery.
Discussion
Colorectal cancer (CRC) is the third most common ma-
lignancy and third leading cause of cancer death in the
USA, with around 136,830 estimated new cases in 2013.
There are several well-defined inherited CRC syndromes
that include HNPCC, familial adenomatous polyposis
(FAP), MutY human homologue-associated polyposis
Fig. 1 Computed tomography with intravenous and oral contrast from
case 2. Coronal section of the abdomen and pelvis. Arrow points to
14.0 × 9.8 × 10.8 cm heterogeneous mass in the right upper quadrant
abutting the ascending colon and duodenum. Oral contrast is seen
within the mass. The fat plane between the mass and the second
segment of the duodenum is obscured
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(MAP), Peutz-Jeghers syndrome, and Juvenile polyposis
syndrome [2]. These syndromes are the result of highly
penetrant germ line mutations that predispose to an
early age onset and high lifetime risk of developing CRC.
HNPCC is the most common of all identified heredi-
tary CRC syndromes with a mean age of colon cancer
diagnosis of 61 years. Loss of expression of mismatch re-
pair genes (MLH1, MSH2, MSH6, PMS2) secondary to
mutations is a characteristic of HNPCC and accounts
for over 97 % of mutations [3]. Recently, germ line mu-
tations in the EPCAM gene that inactivate MSH2 have
also been identified in families of HNPCC patients [3, 4].
These genetic abnormalities are characterized by amplifica-
tions of microsatellite loci throughout the genome resulting
in microsatellite high instability (MSI-H). MSI-H is histo-
logically characterized by tumor-infiltrating lymphocytes,
Crohn’s like lymphocytic reaction, and mucin; tumors are
unique in that they are predominantly proximal to the
splenic flexure, have a low likelihood for regional and dis-
tant metastasis, and the adenoma-to-carcinoma sequence is
accelerated to 2–3 years compared to 7–10 year progres-
sion seen in sporadic cases [4]. Furthermore, HNPCC is
also associated with a predisposition to the development of
extra-colonic malignancies arising from intra-peritoneal or-
gans, as well as the brain and skin. Therefore, appropriate
management of locally advanced CRC in the context of
HNPCC requires special consideration.
For diagnosis, according to the National Comprehensive
Cancer Network (NCCN) guidelines, all patients diag-
nosed with colorectal cancer under the age of 70, or over
the age of 70 and who also meet the Bethesda Guidelines,
should undergo tumor testing by immunohistochemistry
or MSI testing. Greater than 90 % of HNPCC tumors are
MSI-H and/or lack expression of at least one mismatch
repair protein, so while positive screening tests increase
the possibility of HNPCC in younger patients, a definitive
diagnosis cannot be made without identifying a germ line
mutation [2]. Workup of newly suspected HNPCC cases
should be similar to all newly diagnosed cases of colon
cancer. This includes a complete colonoscopy to rule out
synchronous lesions, staging CTs of the chest, abdomen,
and pelvis, and serum CEA to guide post-resection surveil-
lance. Though not recommended for sporadic colon can-
cer, strong consideration for an upper endoscopy and
transvaginal ultrasound should be made because of height-
ened risks for the development of upper gastrointestinal
malignancies and gynecologic malignancies, respectively.
With regard to surgical management, a subtotal colec-
tomy or segmental resection should be offered to patients.
Given the measurable compromises to long-term bowel
function and quality of life, without clear survival advan-
tage, our group favors a segmental colectomy and regional
lymphadenectomy as opposed to subtotal colectomy [5, 6].
In the cases presented in this paper, genetic testing and
confirmation of HNPCC was performed post-operatively,
so while there was a high suspicion for HNPCC during
pre-operative evaluation, surgical decision-making was per-
formed in the context of locally advanced CRC with poten-
tially curative resection. For these cases, much has been
written about locally advanced, sporadic CRC with inva-
sion into the pancreatic head or duodenum requiring pan-
creaticoduodenectomy. Multi-visceral resection achieves an
oncologically sound operation associated with prolonged
overall survival, reduced local recurrence rates, and accept-
able perioperative morbidity and mortality when performed
by experienced surgeons [7, 8]. Recently, investigators have
reported that a more extensive en bloc pancreaticoduode-
nectomy compared to an en bloc local resection is associ-
ated with an improved 5-year overall survival [9]. However,
few reports address this surgical scenario in the context of
HNPCC. While the basic oncologic principles of primary
resection still apply, 25 % of HNPCC patients who undergo
a segmental colectomy will develop metachronous CRC
after the index diagnosis [10]. This is why some surgeons
advocate for an upfront total abdominal colectomy and
ileorectal anastomosis, but there has yet to be any data





Fig. 2 Endoscopy images, gross pathology, and histopathology from
case 2. a Colonoscopy revealed an ulcerated, partially obstructing,
large mass in the transverse colon (marked by asterisk). The pediatric
colonoscope could not completely traverse this large mass due to
tumor obstruction and alteration in the normal colon anatomy. b
Upper endoscopy showed a large malignant ulcerated mass
(marked by asterisk) with no bleeding in the second part of the
duodenum. c Part of the surgical specimen including colon (marked
by single arrow), duodenum (marked by double arrow), with the
mass (marked by asterisk) with a diffusely mucinous appearance. d
Hematoxylin and eosin stain of primary colonic adenocarcinoma
(viewed at ×40) with large pools of mucin evident. The tumor was
14 cm, low grade mucinous adenocarcinoma of the colon with loss
of mismatch repair proteins and high microsatellite instability. There
was mild to moderate intratumoral lymphocytes, mild to moderate
peritumor lymphocytes, with low grade tumor budding, and no
lymphovascular invasion. Margins were negative and 22 lymph
nodes were negative (not shown)
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undergoing such an approach [6]. A prophylactic total or
subtotal colectomy in the context of a multi-visceral resec-
tion would seem unnecessary. Regardless, in non-emergent
cases, the benefits and risks of local vs extended resection
should be discussed with patients who are MMR deficient
with confirmatory genetic testing, keeping in consideration
patient preference, the effect of bowel function on quality
of life, and the predicted post-operative compliance to
surveillance.
The current standard for adequate staging of right-sided
colon cancers remains at least 12 lymph nodes, as es-
poused by the NCCN [2]. Interestingly, MSI-H is associ-
ated with higher lymph node yields in a prospective study
of 204 patients with colon cancer, stages I–III (67 % of pa-
tients had ≥12 lymph nodes sampled, while 79 % of pa-
tients with microsatellite instability had ≥12 lymph nodes
sampled (OR 2.5, p = 0.007)); 5.6 % of the total lymph
nodes were positive for metastasis [11] compared with
46 % of microsatellite stable (MSS) CRC resections in a
separate study [12]. This raises the question of whether
the proportion of positive lymph nodes may be a better
prognosticator than the absolute number [13]. However,
the significant values for such lymph node ratios are still
under investigation and even with a ratio, there will still
need to be an absolute minimum of lymph nodes recom-
mended for retrieval.
The paradigm of chemotherapy for locally advanced
CRC is changing. Recommendations for the use of pre-
operative neoadjuvant chemotherapy to provide better
local control for R0 resection have been increasing, citing
the theoretical eradication of micrometastases and reduced
perioperative tumor shedding, as well as downstaging with
better progression-free and overall survival. More recently,
there is evidence of added benefit in combining neoadju-
vant and adjuvant treatment for CRC, as was performed in
case 2 [14]. However, the benefit of chemotherapy in pa-
tients with HNPCC, regardless of timing, is unclear. Be-
cause of the distinct molecular background of MSI-H
tumors, it has been suggested that they may be less respon-
sive to traditional CRC chemotherapeutic agents. In a
retrospective study from the Netherlands, there was no dif-
ference in 5-year overall survival in patients with stage III
colon cancer of HNPCC families in comparing patients
treated with and without adjuvant 5FU (70 % 5-year sur-
vival for both the group that received adjuvant therapy and
the group that did not) [15]. The benefit of chemotherapy
in MSI-H CRC in HNPCC requires further investigation.
Conclusions
Our two cases have several striking similarities that high-
light important issues in the surgical management of
HNPCC. Each patient presented with proximal, locally ad-
vanced, non-metastatic CRC. Careful pre-operative plan-
ning was required to perform multi-organ, en bloc
resections with negative surgical margins. Despite aggres-
sive lymphadenectomies, neither patient had lymph node
Table 1 Comparison of studies with regards to interventions for colorectal cancer
Authors Year Number of patients Intervention evaluated Main conclusions
You et al. 2008 522 Quality of life (QOL) after extended (201) vs segmental (321)
colon resection
Extended resection yielded compromised
bowel function, with decreased QOL
Zhang et al. 2013 14 En bloc pancreaticoduodenectomy (PD) and right
hemicolectomy in right colon cancer
Outcomes no worse than stage-matched
patients without adjacent organ
involvement
Temple et al. 2014 635 PD (607) vs PD with colon resection (28) No significant difference in post-operative
mortality
Cirocchi et al. 2014 53 En bloc (39) vs local resection (14) in locally advanced right
colon cancer
En bloc resection improved overall 5-year
survival
Kalady et al. 2010 296 Segmental (253) vs total colectomy (43) in HNPCC Segmental resection increases the risk of
metachronous colon cancer
Berg et al. 2013 204 Impact of tumor genetics on lymph node harvest in stage
I–III colon cancer
Node harvest was greatest for cancers
with MSI but without KRAS/BRAF
Samdani et al. 2015 256 Effect of mismatch repair deficiency on lymph node yield in
colorectal cancer
Mismatch repair deficiency did not
predict lymph node yield
Sugimoto et al. 2015 4172 Prognostic value of lymph node ratio in stage III colon cancer Lymph node ratio, with a cutoff value of
0.18, was a significant independent
prognostic factor
Hong et al. 2014 321 Comparison of adjuvant chemotherapy (fluorouracil and
leucovorin (161) vs FOLFOX (160)) in stage II–III rectal cancer
after neoadjuvant chemoradiotherapy and resection
Adjuvant FOLFOX improved survival





2004 92 Effect of adjuvant therapy with 5-FU (28) vs no adjuvant
therapy (64) in stage III colon cancer of HNPCC
5-year survival did not differ
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metastases arising from their MSI-H tumor. After com-
pleting adjuvant chemotherapy, each patient remains
disease free at 4.5 and 2.0 years from surgery, respect-
ively. Intriguingly, both patients were also diagnosed
with DVTs prior to surgery. However, there is little in-
formation available on whether HNPCC confers a risk
of hypercoagulability.
Locally advanced CRC involving the foregut is a rare
presentation of HNPCC. A well-planned, multi-modality
treatment approach is necessary for treatment. A review
of the literature, summarized in Table 1, supports that a
pancreaticoduodenectomy with en bloc segmental colec-
tomy and regional lymphadenectomy provides patients
with the potential for cure.
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